Related Experiment Video
Updated: Aug 6, 2026

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors
Published on: June 8, 2022
Harnessing the structural determinants amenable for polypharmacological behavior of 7D against Sirt1 and CXCR3
Kiran Bharat Lokhande1, Dhani Ram Mahato1, Shailendra Asthana1
1Computational Biophysics and CADD Group, Computational and Mathematical Biology Centre (CMBC), BRIC-Translational Health Science and Technology Institute, Faridabad, Haryana 121001, India.
Abstract:
Discovery of polypharmacological agents, inhibiting targets, either the same or diverse pathways, is an emerging paradigm in drug discovery. Designing such a candidate is challenging due to the lack of structural and dynamical consensus determinants of interacting partners. We identified a dual target inhibitor, 7D (mono-peptide of benzimidazole), a dengue antiviral lead against host proteins (Sirt1 and CXCR3) to underpin polypharmacological features. Targeting host proteins represents a compelling antiviral strategy as the modulation of host-regulated pathways can suppress dengue virus replication without directly engaging viral proteins, thereby minimizing the risk of resistance. Genesis of 7D discovery, critical determinants were identified for its rational designing to achieve Sirt1 selectivity. Focusing on the antiviral target, CXCR3 was explored via virtual screening of the in-house compound library. Among identified candidates, 7D appeared to be a potential hit, confirmed via in vitro and in vivo means, leading the basis to underscore the determinants responsible for polypharmacological behavior, paving a way for feature-based designing of such candidates.
Related Concept Videos
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
